Annotation Detail
Information
- Associated Genes
- KRAS
- Associated Variants
-
KRAS MUTATION
KRAS MUTATION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- Meta-Analysis of 12 studies with 2,266 patients (54 % were KRAS wt). The pooled response rates (RR) for KRAS wild-type (wt) versus mutated (mut) patients were 54.8 and 48.3 %, respectively (OR 1.42, P = 0.02). Median PFS in KRAS wild-type patients was significantly longer than in KRAS mut patients (HR = 0.85; 95 % confidence interval (CI) 0.74-0.98; P = 0.02). Median OS in wild-type KRAS patients compared was significantly better than in KRAS mut patients (HR = 0.65; 95 % CI 0.46-0.92; P = 0.01).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/1139
- Gene URL
- https://civic.genome.wustl.edu/links/genes/30
- Variant URL
- https://civic.genome.wustl.edu/links/variants/336
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Bevacizumab,Chemotherapy
- Evidence Level
- B
- Clinical Significance
- Resistance
- Pubmed
- 23828442
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Bevacizumab | Resitance or Non-Reponse | true |
| Chemotherapy | Resitance or Non-Reponse | true |